- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
Review, Journal: Treatment and new evidences in neuromyelitis optica spectrum disorder (Pubmed Central) - Oct 22, 2021 This article discusses off-label azathioprine and mycophenolate mofetil in the treatment of NMOSD and reviews the evidence-based clinical aspects of B/plasma cell depletion, antagonization of IL-6 signaling and blocking the complement pathway...In the recent two years, phase 3 clinical trials provided class I evidence for the efficacy and safety of rituximab (anti-CD20), inebilizumab (anti-CD19), tocilizumab (anti-IL6R), satralizumab (anti-IL6R), and eculizumab (anti-C5) in combination with other immunosuppressants or in monotherapy...Immunosuppression is recommended in NMOSD during pregnancy and lactation, and this should be considered for optimal selection of treatment in fertile female patients. The new monoclonal antibodies broadened treatment options NMOSD, and the treatment strategy of MOGAD has become more straightforward.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Journal: Neuromyelitis Optica Spectrum Disorders - Present Insights and Recent Developments (Pubmed Central) - Oct 22, 2021 The achievements of the last 15 years have essentially shaped the diagnostic methods and therapy of Neuromyelitis optica spectrum disorders (NMOSD): from discovery of aquaporin 4 antibodies and further development of diagnostic criteria the path has led to the approval of eculizumab and satralizumab as first disease modifying treatments in Europe. This article should give an overview on the present insights and future treatment options.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Clinical, Journal: Satralizumab in the treatment of neuromyelitis optica spectrum disorder. (Pubmed Central) - Oct 16, 2021 Here, we review the two randomized, double-blind, Phase III trials that investigated the subcutaneous administration of satralizumab as add-on treatment and monotherapy. Both studies revealed positive effects concerning the reduction of relapse risk for AQP4 seropositive NMOSD patients and generally good tolerability.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Journal: Recent advances in the treatment of neuromyelitis optica spectrum disorders. (Pubmed Central) - Sep 29, 2021 The favourable safety profile of satralizumab was sustained with long-term treatment. Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD.
- |||||||||| Enspryng (satralizumab) / Roche
Journal: Satralizumab-mwge. (Pubmed Central) - Sep 23, 2021 Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD. No abstract available
- |||||||||| Uplizna (inebilizumab) / Horizon Therapeutics, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] COVID-19 in neuromyelitis optica spectrum disorder patients in Poland (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1578; Most of the NMOSD patients under the care of our site had a favourable course of SARS-CoV-2 infection. Continued data collection is needed to increase understanding of SARS-CoV-2 infection impact on the course of NMOSD in patients.
- |||||||||| Enspryng (satralizumab) / Roche
Journal: Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) - Sep 8, 2021 High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment. Satralizumab appears to be safe and effective as monotherapy or in combination with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
[VIRTUAL] Current standard of care and new emerging treatments in NMOSD (Stream 7 Educational Sessions) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1401; Classical immunosuppressive therapies (IST) such as azathioprine, mycophenolate mofetil with and without low-dose oral steroids showed efficacy in non-controlled trials and have been widely used in the past to reduce relapses...Subsequently, after successful clinical trials, three monoclonal antibodies have been approved for the treatment of AQP4-IgG positive NMOSD since 2019: the C5 complement inhibitor eculizumab, the IL-6 receptor antibody satralizumab and the anti-CD19 antibody inebilizumab...IST as well as rituximab and tocilizumab as off-label therapies are usually used for those patients. In light of the new therapeutic landscape the current standard of care in NMOSD is reviewed and treatment recommendations discussed for AQP4-IgG positive and negative NMOSD patients in this educational session.
- |||||||||| Uplizna (inebilizumab) / Horizon Therapeutics, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] COVID-19 in neuromyelitis optica spectrum disorder patients in Poland (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_224; Most of the NMOSD patients under the care of our site had a favourable course of SARS-CoV-2 infection. Continued data collection is needed to increase understanding of SARS-CoV-2 infection impact on the course of NMOSD in patients.
- |||||||||| Enspryng (satralizumab) / Roche
Review, Journal: Satralizumab: First Approval. (Pubmed Central) - Jul 9, 2021 Satralizumab is under regulatory review in the EU and USA, and is undergoing clinical development in several countries worldwide. This article summarizes the milestones in the development of satralizumab leading to this first approval for the treatment of NMOSD.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Review, Journal: Immune reconstitution therapy in NMOSD. (Pubmed Central) - Jul 8, 2021 In NMO, control the complement (eculizumab), reconstitute the immune system (AHSCT), transition to immunomodulation (satralizumab) and reserve immunosuppression (inebilizumab) as 4th line. AHSCT might also be used as rescue therapy for severe breakthrough disease after NMO-DMTs.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Journal: Neuromyelitis Optica Spectrum Disorder (Pubmed Central) - May 26, 2021 Currently, there are additional options for therapy with biopharmaceutical agents such as eculizumab, satralizumab, rituximab, or inebilizumab to prevent relapse of the disease. These new options can clearly exceed or surpass the usual treatments and should be considered positively in aggressive cases of NMOSD.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
Clinical, Review, Journal: Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. (Pubmed Central) - May 15, 2021 New molecules: Eculizumab, Tocilizumab, Satralizumab are good options for treatment. Drugs like Azathioprine and Mycophenolate are effective, but with a worse risk-benefit ratio, therefore, they are useful alternatives in places that do not have access to monoclonal antibodies.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. (Pubmed Central) - Apr 7, 2021 Further, the authors summarize the most recent findings on the use of anti-IL-6R monoclonal antibodies, tocilizumab and satralizumab, in the treatment of NMOSD.Expert opinion: A better understanding of the role of cytokines in NMOSD may provide the neurologist with novel therapies for this disease. IL-6R appears to be a central hub to NMOSD pathogenesis and a relevant therapeutic target.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Clinical, Review, Journal: New Therapeutic Landscape in Neuromyelitis Optica. (Pubmed Central) - Apr 7, 2021 Reliable biomarkers to guide therapy decisions are urgently needed. There is a plethora of promising investigational therapies currently in the pipeline with exciting and novel mechanisms of action.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Journal: Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) - Mar 27, 2021 Monoclonal antibodies targeting terminal complement (eculizumab), CD19 (inebilizumab), and the interleukin-6 receptor (satralizumab) have demonstrated efficacy in NMOSD attack prevention in recent phase 3 trials and have gained subsequent regulatory approval in the USA and other countries. We aim to review the evidence supporting the efficacy of these new drugs.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
Review, Journal: Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. (Pubmed Central) - Mar 23, 2021 These trials support the efficacy of rituximab and tocilizumab and led to the FDA approval of eculizumab, satralizumab and inebilizumab for NMOSD. Our review provides an update on these evidence-based disease-modifying therapies and discussed the treatment of acute relapses in NMOSD.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Journal: Current and Emerging Biologics for the Treatment of Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) - Feb 23, 2021 The interleukin-6 receptor inhibitor satralizumab and anti-CD19 antibody inebilizumab have published positive phase III trial results and await approval in the near future...Although we will have even more evidence-based therapy options in the future, empirically used medications will keep their importance for now. The potential effect of new medications in AQP4 antibody seronegative NMOSD and patients with an NMOSD phenotype and antibodies to myelin oligodendrocyte glycoprotein (MOG) remains to be determined.
- |||||||||| Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
Journal: Emerging drugs for the treatment of neuromyelitis optica. (Pubmed Central) - Feb 4, 2021 For the first time in this disease, class I treatment evidence is available, but long-term data will be necessary to confirm the overall promising study results of the compounds close to approval. While drug development still centers around AQP4 antibody seropositive patients, current and future research requires consideration of possible diverging treatment demands for the smaller group of seronegative patients and patients with presence of MOG antibodies.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Review, Journal: New therapies for neuromyelitis optica spectrum disorder. (Pubmed Central) - Jan 29, 2021 WHERE NEXT?: Despite the rarity of neuromyelitis optica spectrum disorder, a relative abundance of preventive treatment options now exists. In the future, trials should focus on areas of unmet need, including aquaporin-4 seronegative disease, and on development of treatments for acute relapses and for recovery from autoimmune attacks in the CNS.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] NMO and antiMOG: Updates on Diagnosis and Treatment (Scientific Program Auditorium) - Jan 27, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_79; The availability of proven attack prevention biologics for NMOSD provides new hope for patients with NMOSD. Improved understanding of MOGAD phenotype, natural history and immunopathologic mechanisms of disease combined with optimized MOG-IgG detection assays will allow development of international diagnostic criteria and assist in drug trial design.
|